

PRESS RELEASE

Ipca Laboratories Q1 FY16 Unaudited Financial Results

Mumbai, July 30, 2015: Ipca Laboratories Limited today announced its unaudited financial results for the first quarter ended 30th June, 2015 of the financial year 2015-16.

The income and profitability of the Company was impacted in Q1FY16 due to:

- US FDA import alert on three manufacturing units;
- Lower anti-malarial institutional business; and
- Business impact in the emerging markets due to currency fluctuations.

The Company is implementing comprehensive remedial measures at all its manufacturing sites to ensure quality and regulatory compliances and is confident that it will regain all its regulatory approvals in near future.

The Ratlam Active Pharmaceutical Ingredients (APIs) manufacturing unit of the Company was recently inspected and approved by the regulatory authorities of Europe, Australia and WHO-Geneva.

Key Financials of Q1FY16

- Net Total Income down 19% at Rs. 762.10 crores.
- Indian formulations income up 8% at Rs. 318.05 crores.
- Exports Income down 34% at Rs. 376.97 crores.
- EBIDTA margin @ 10.84% in Q1FY16 as against @24.67% in Q1FY15.
- Net Profit at Rs. 18.89 crores down 86%.

Q1FY16 at a glance			(Rs. Crores)
Particulars	Q1FY16	Q1FY15	Growth
Net Total Income	762.10	942.25	-19%
Export Income	376.97	570.87	-34%
EBITDA	82.18	230.92	-64%
Profit / (Loss) before Forex (gain) / loss and tax	38.76	180.32	-79%
Forex (gain) / loss	11.63	(2.26)	-
Net Profit after Forex (gain) / loss and tax	18.89	136.74	-86%
Earnings per share of Rs. 2/- each (Rs.)	1.50	10.84	-86%



Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, CTS NO. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6613

E: ipca@ipca.com CIN: L24239MH1949PLC007837

Q1FY16 Revenue break-up			(Rs. Crores)
Particulars	Q1FY16	Q1FY15	Growth
Formulations			
Domestic	318.05	293.19	8%
Exports	224.83	387.73	-42%
Total Formulations	542.88	680.92	-20%
APIs			
Domestic	55.96	64.14	-13%
Exports	152.14	183.14	-17%
Total APIs	208.10	247.28	-16%
Grand Total	750.98	928.20	-19%

About Ipca Laboratories:

Ipca is a fully integrated pharmaceutical company with a strong thrust on exports which now account for 49% of Company's income. Ipca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients.



Premchand Godha
Chairman & Managing Director



Contact Information:

Harish P. Kamath, Corporate Counsel & Company Secretary at harish.kamath@ipca.com or on +91-22-6210 6050

Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, CTS NO. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6613

E: ipca@ipca.com CIN: L24239MH1949PLC007837